This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-09-2068v1 69/18/7175    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Antonescu, C. R. Articles by Maki, R. G. PubMed PubMed Citation Articles by Antonescu, C. R. Articles by Maki, R. G.

KDR Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors

Departments of ¹ Pathology, ² Epidemiology and Biostatistics, ³ Surgery, and ⁴ Medicine, Memorial Sloan-Kettering Cancer, New York, New York

Requests for reprints: Cristina R. Antonescu, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Phone: 212-639-5721; Fax: 212-717-3203; E-mail: antonesc{at}mskcc.org.

Key Words: angiosarcoma • KDR • kinase inhibitors • sorafenib • sunitinib

Angiosarcomas (AS) represent a heterogeneous group of malignant vascular tumors occurring not only in different anatomic locations but also in distinct clinical settings, such as radiation or associated chronic lymphedema. Although representing only 1% to 2% of soft tissue sarcomas, vascular sarcomas provide unique insight into the general process of tumor angiogenesis. However, no molecular candidates have been identified to guide a specific therapeutic intervention. By expression profiling, AS show distinct up-regulation of vascular-specific receptor tyrosine kinases, including TIE1, KDR, SNRK, TEK, and FLT1. Full sequencing of these five candidate genes identified 10% of patients harboring KDR mutations. A KDR-positive genotype was associated with strong KDR protein expression and was restricted to the breast anatomic site with or without prior exposure to radiation. Transient transfection of KDR mutants into COS-7 cells showed ligand-independent activation of the kinase, which was inhibited by specific KDR inhibitors. These data provide a basis for the activity of vascular endothelial growth factor receptor–directed therapy in the treatment of primary and radiation-induced AS. [Cancer Res 2009;69(18):7175–9]